Analyzing R&D Budgets: Genmab A/S vs Viridian Therapeutics, Inc.

Biotech R&D: Genmab vs. Viridian's Decade of Growth

__timestampGenmab A/SViridian Therapeutics, Inc.
Wednesday, January 1, 2014505679000293000
Thursday, January 1, 20154876560001002000
Friday, January 1, 2016660876000888000
Sunday, January 1, 201787427800019623000
Monday, January 1, 2018143115900030421000
Tuesday, January 1, 2019238600000034794000
Wednesday, January 1, 2020313700000028304000
Friday, January 1, 2021418100000056886000
Saturday, January 1, 20225562000000100894000
Sunday, January 1, 20237630000000159765000
Monday, January 1, 20249748000000
Loading chart...

Unleashing the power of data

A Decade of Innovation: R&D Spending in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) are the lifeblood of innovation. Over the past decade, Genmab A/S and Viridian Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments. Genmab A/S, a leader in antibody therapeutics, has seen its R&D expenses skyrocket by over 1,400% from 2014 to 2023, reflecting its commitment to groundbreaking research. In contrast, Viridian Therapeutics, Inc., a smaller player in the field, has increased its R&D spending by an impressive 54,000% during the same period, albeit from a much smaller base. This stark difference highlights the diverse strategies within the biotech sector, where established giants and emerging innovators alike are racing to develop the next big breakthrough. As we look to the future, these investments will likely shape the landscape of healthcare and medicine.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025